Close menu




January 7th, 2022 | 12:51 CET

BioNTech, XPhyto, Valneva: 3 stocks for next week?

  • Biotechnology
Photo credits: pixabay.com

Omicron is slowly but surely making its presence felt in Germany. After the holidays, when first there is less testing, and secondly the fax machines in German health offices are at a standstill, the official statistics are becoming a little more accurate again. There are already signs of where the journey might be headed. If the past week's growth remains constant, the incidence could already be above the 500 mark in 7 to 10 days. Although such projections are subject to error, it is worth looking at the typical pandemic stocks.

time to read: 3 minutes | Author: Nico Popp
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , XPHYTO THERAPEUTICS | CA98421R1055 , VALNEVA SE EO -_15 | FR0004056851

Table of contents:


    BioNTech: This share could turn around

    The BioNTech share has attracted attention in recent weeks with price fluctuations - the value fell by 38% in one month. Currently, the share is preparing to turn upwards again from the low of last November. In line with the chart situation, good news has come to light for BioNTech. Together with Pfizer, the Company has developed a vaccine against shingles triggered by herpes viruses. Shingles mainly affects older people. A vaccine could become a big seller. At the same time, there are reports of a new mutant from France that is said to be genetically even more different from the original type of coronavirus.

    Both pieces of news are positive for BioNTech: Since the Company can react flexibly to new challenges and already has the image of a Mercedes among vaccine manufacturers, the cash register should continue to ring for the Mainz-based Company. In addition, more and more new Corona variants indicate that BioNTech will also be responsible for the fourth and possibly fifth prick. The share could become exciting in the coming days.

    XPhyto: Several irons in the fire

    The situation is also interesting for XPhyto, a specialist in diagnostics and drug delivery. The Canadian Company has acquired several German companies in recent months and years and therefore has good business relations in Germany. Its flagship product is the Company's rapid PCR test, which promises PCR-quality results after just 25 minutes. In times when even vaccinated people are becoming increasingly infected and remain under the radar with mild symptoms, the sensitive PCR tests could be the key to greater safety. XPhyto wants to bring its products to customers primarily at airports. There, a rapid PCR test between landing and baggage claim could provide the highest level of security. In addition to corona tests, Xphyto also offers oral health tests.

    Other areas of activity for the Company include innovative delivery forms, such as active ingredient patches. Studies suggest that certain active ingredients can be used better and more cost-effectively, thanks to alternative delivery forms. On the other hand, the Company's activities in the field of psychedelics are speculative: XPhyto wants to fight depression with mescaline and other substances. A few months ago, researchanalyst.com wrote about this in a research piece on XPhyto: "While this topic has not yet struck a chord with physicians and decision-makers in the healthcare sector in Germany, people in North America are more open-minded. With XPhyto's presence in both regions, the Company can advance this speculative business area within a constructive environment." XPhyto's stock remains highly speculative but should be on the minds of short-term investors, especially in the coming days. The share is well-positioned if the market swings back into pandemic mode.

    Valneva: What are the authorities doing?

    In recent weeks, Valneva's shares have also been heavily traded on the market. These days, the manufacturer of a vaccine candidate is likely to be looking eagerly to the European Medicines Agency (EMA). There, the French manufacturer's inactivated vaccine is currently being tested. However, it remains to be seen how long this review will last and whether the parallel studies, such as the use of the vaccine as a booster, can still have a positive effect during the current wave. The share price has almost halved from its high a few weeks ago. The stock is a hot potato.


    Instead of relying on the authorities, investors would be better off betting on established players, such as BioNTech. Here, the conditions are good to take off with new vaccine variants and entirely new vaccines based on mRNA. XPhyto could be an insider tip. Here, three promising investment stories come together. However, the value is extremely speculative and is in a downward trend.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Nico Popp on November 30th, 2022 | 13:33 CET

    Advances in the fight against cancer: Arcus Biosciences, Gilead Sciences, Defence Therapeutics, BioNTech

    • Biotechnology
    • Covid19
    • Cancer

    Research studies from 2020 show that 72% of Germans fear cancer. However, very few people want to admit to these fears. But precisely because the subject is a big taboo, it is worth looking at the latest achievements in research. Many companies worldwide have long been fighting the epidemic - and making astonishing progress. Just recently, a US biotech announced encouraging study results. Other companies have yet to launch promising studies. We provide an overview and outline opportunities from an investor's perspective.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Fabian Lorenz on November 24th, 2022 | 12:40 CET

    New year, rising prices? BASF, BioNTech and Manuka Resources - Shares in check

    • Mining
    • Commodities
    • Biotechnology
    • chemicals

    As the stock market year 2022 draws to a close, we look ahead to 2023. New year, rising prices? That is what many stock market players are hoping for. The chances are that we will see rising indices again with the end of interest rate hikes in the coming year. Today, we look at three companies likely to attract attention in 2023. At BioNTech, the research pipeline is full to bursting, and there are numerous study results to come. BASF is attractive due to its low valuation and high dividend yield. However, analysts warn of a write-off risk. Manuka Ressources convinces with a profitable core business, and an exciting project in the field of critical raw materials could lead to a revaluation.

    Read